- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
NW Bio Appoints Two New Independent Directors with Biotech/Pharma Expertise and Cybersecurity/Investigations Expertise
Northwest Biotherapeutics (NASDAQ:NWBO) announced that it is expanding its Board of Directors through the appointment of Ms. Susan Bayh and Ambassador Cofer Black as independent Directors.
Northwest Biotherapeutics (NASDAQ:NWBO) announced that it is expanding its Board of Directors through the appointment of Ms. Susan Bayh and Ambassador Cofer Black as independent Directors.
According to the company’s press release:
Ms. Bayh brings to NW Bio 25 years of experience relating to the pharmaceutical and biotech industries, including in immunotherapies for cancer. She has served on the Boards of Wellpoint, Inc., a Fortune 30 health insurance company with the Blue Cross brand in fifteen states, as well as on the board of eight public biotech companies, and three other companies, including in multiple leadership positions. Several of these biotech companies have been successfully acquired. She also served as in-house counsel at a major pharma company for five years, handling FDA pre-approval and post-approval matters.
Ambassador Black is internationally recognized in the intelligence community and brings to NW Bio extensive experience in cybersecurity, counterintelligence, and investigations and related matters. Ambassador Black served a 28-year career in the CIA, including as Director of the Counterterrorist Center managing 1,300 professionals and an annual budget in excess of $1 billion. In that capacity, he served as the focal point for the intelligence community, supervised the Interagency Counterterrorism Board, was responsible for CIA all-source analysis, directed all CIA counterterrorism operations abroad, including covert action, and defined global intelligence strategy for the U.S. Ambassador Black was awarded the Distinguished Intelligence Medal (the CIA’s highest award for achievement) as well as numerous other awards.
Linda Powers, CEO of NW Bio, stated:
We are excited to have received the necessary approvals and to have two such high caliber professionals as Ms. Bayh and Ambassador Black join our Board. They bring extensive expertise in two different areas of major importance and value for NW Bio as we expand and strengthen our organization and we work to accelerate our progress.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.